<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439293</url>
  </required_header>
  <id_info>
    <org_study_id>C16047</org_study_id>
    <secondary_id>U1111-1202-6022</secondary_id>
    <secondary_id>2017-003977-32</secondary_id>
    <nct_id>NCT03439293</nct_id>
  </id_info>
  <brief_title>A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)</brief_title>
  <official_title>A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the percentage of participants with a response of&#xD;
      very good partial response (VGPR) or better to IDd treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The regimen being tested in this study is the combination of ixazomib, daratumumab, and&#xD;
      dexamethasone. This study will look at the efficacy and safety of IDd in people who have&#xD;
      RRMM.&#xD;
&#xD;
      The study will enroll approximately 60 Participants. Participants will be assigned to the&#xD;
      treatment group:&#xD;
&#xD;
      â€¢ Ixazomib 4.0 mg + Daratumumab 16.0 mg/kg + Dexamethasone 20 mg&#xD;
&#xD;
      All participants will be asked to take Ixazomib on Days 1, 8 and 15 of each 28-day cycle plus&#xD;
      Daratumumab on Days 1, 8, 15 and 22 of each 28-day cycle for Cycles 1 and 2, on Days 1 and 15&#xD;
      of each 28-day cycle for Cycles 3 through 6 and on Day 1 of each 28-day cycle for Cycle 7 and&#xD;
      beyond plus Dexamethasone orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle.&#xD;
&#xD;
      This multi-center trial will be conducted in the United States, Czech Republic, France,&#xD;
      Poland, Greece and the Netherlands. The overall time to participate in this study is 5 years.&#xD;
      Participants will make multiple visits to the clinic, and every 12 weeks after PD until death&#xD;
      or termination of the study by the sponsor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 13, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants VGPR or Better</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Response will be assessed using International Myeloma Working Group (IMWG) Criteria. VGPR is defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90 percent (%) or greater reduction in serum M-protein plus urine M-protein level less than (&lt;) 100 milligram (mg) per 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>PFS is defined as time from date of first dose of drug to date of first documentation of progressive disease (PD) or death from any cause, whichever occurs first. PD: Increase of 25% from lowest response value in any of following: Serum M component with increase greater than or equal to (&gt;=) 0.5 grams per deciliter (g/dL); serum M component increases &gt;= 1 g/dL are sufficient to define relapse if starting M component is &gt;= 5 g/dL and/or; Urine M component (absolute increase must be &gt;= 200 mg/24 hours) and/or, development of new/definite increase in size of existing bone lesions/soft tissue plasmacytomas, development of hypercalcemia that can be attributed to plasma cell proliferative disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>TTP is defined as the time from the first dose of any study drug treatment to the date of the first documented progressive disease (PD). PD: Increase of 25% from lowest response value in any of following: Serum M component with increase &gt;= 0.5 g/dL; serum M component increases &gt;=1 g/dL are sufficient to define relapse if starting M component is &gt;= 5 g/dL and/or; Urine M component (absolute increase must be &gt;= 200 mg/24 hours) and/or, development of new/definite increase in size of existing bone lesions/soft tissue plasmacytomas, development of hypercalcemia that can be attributed to plasma cell proliferative disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>OS is defined as the time from the date of first dose of any study drug treatment to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>ORR is defined as participants with complete response (CR), VGPR and partial response (PR). CR: Negative immunofixation of serum and urine, disappearance of any soft tissue plasmacytomas, and &lt;5% plasma cells in bone marrow; normal free light chain (FLC) ratio of 0.26-1.65; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;=90% reduction in serum M-protein + urine M-protein level &lt;100 mg/24 hours; and PR: &gt;=50% reduction of serum M protein and reduction in 24-hour urinary M protein by &gt;=90%/to &lt;200 mg/24 hours; In addition, if present at baseline, &gt;=50% reduction in size of soft tissue plasmacytomas; no known evidence of progressive/new bone lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Response (TTR)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>TTR is defined as the time from first dose of any study drug treatment to the date of first documentation of PR or better. PR is defined as &gt;=50% reduction of serum M protein and reduction in 24-hour urinary M protein by &gt;=90%/to &lt;200 mg/24 hours; In addition, if present at baseline, &gt;=50% reduction in size of soft tissue plasmacytomas; no known evidence of progressive/new bone lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>DOR is defined as the time from the date of first documentation of PR or better to the date of the first documented PD among participants who responded to the treatment. PR is defined as &gt;=50% reduction of serum M protein and reduction in 24-hour urinary M protein by &gt;=90%/to &lt;200 mg/24 hours; In addition if present at baseline, &gt;=50% reduction in size of soft tissue plasmacytomas; no known evidence of progressive/new bone lesions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib, 4 mg, capsules, orally, on Days 1, 8 and 15 of each 28-day cycle along with daratumumab, 16 milligram per kilogram (mg/kg), intravenously (IV), on Days 1, 8, 15 and 22 of Cycles 1 and 2, on Days 1 and 15 (every 2 weeks) for Cycles 3 to 6 and on Day 1 (every 4 weeks) for Cycle 7 and beyond along with dexamethasone, 20 mg, tablets, orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle until progressive disease (PD), have an unacceptable toxicity, or withdraw consent, or when the study has completed or until the sponsor terminates the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixazomib</intervention_name>
    <description>Ixazomib capsule.</description>
    <arm_group_label>Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg</arm_group_label>
    <other_name>NINLARO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Daratumumab IV infusion.</description>
    <arm_group_label>Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone tablets.</description>
    <arm_group_label>Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have measurable disease by at least 1 of the following measurements:&#xD;
&#xD;
               -  serum M-protein &gt;=1 gram per liter (g/dL) (&gt;=10 g/L).&#xD;
&#xD;
               -  urine M-protein &gt;=200 mg/24 hours.&#xD;
&#xD;
          2. Have documented evidence of progressive disease (PD) on or after their last regimen as&#xD;
             defined by IMWG criteria. All participants must have received between 1 to 3 prior&#xD;
             therapies for MM (a prior therapy is defined as 2 or more cycles of therapy given as a&#xD;
             treatment plan for MM [example, a single-agent or combination therapy or a sequence of&#xD;
             planned treatments such as induction therapy followed by autologous stem cell&#xD;
             transplant (SCT) and then consolidation and/or maintenance therapy]).&#xD;
&#xD;
          3. Have achieved a response (partial response (PR) or better) to at least 1 prior&#xD;
             therapy.&#xD;
&#xD;
          4. Have an Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2.&#xD;
&#xD;
          5. Must meet the following laboratory criteria:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt;=1000 per cubic millimeter (/mm^3).&#xD;
&#xD;
               -  Platelet count &gt;=75,000/mm^3.&#xD;
&#xD;
               -  Total bilirubin less than or equal to (&lt;=) 1.5*the upper limit of the normal&#xD;
                  range (ULN) (except for Gilbert syndrome: direct bilirubin &lt;=2*ULN).&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt;=3*ULN.&#xD;
&#xD;
               -  Calculated creatinine clearance &gt;=50 mL/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have undergone prior allogenic bone marrow transplantation.&#xD;
&#xD;
          2. Have received prior ixazomib at any time or daratumumab or other anti-CD38 therapies,&#xD;
             except as part of initial therapy if this was stopped to move on to SCT and the&#xD;
             participant did not progress on anti-CD38 treatment.&#xD;
&#xD;
          3. Are refractory to bortezomib or carfilzomib at the last exposure before this study&#xD;
             (defined as participants having PD while receiving bortezomib or carfilzomib therapy&#xD;
             or within 60 days after ending bortezomib or carfilzomib therapy).&#xD;
&#xD;
          4. Are planning to undergo SCT prior to PD on this study (ie, these participants should&#xD;
             not be enrolled in order to reduce disease burden prior to transplant).&#xD;
&#xD;
          5. Are receiving systemic treatment with strong Cytochrome P450 3A4 (CYP3A) inducers&#xD;
             (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, St. John's&#xD;
             wort) within 14 days before randomization.&#xD;
&#xD;
          6. Has received autologous SCT within 12 weeks before the date of study treatment.&#xD;
&#xD;
          7. With known chronic obstructive pulmonary disease (COPD) with a forced expiratory&#xD;
             volume in 1 second (FEV1) &lt;50% of predicted normal. Note: FEV1 testing is required for&#xD;
             participants suspected of having COPD and participants must be excluded if FEV1 is&#xD;
             &lt;50% of predicted normal.&#xD;
&#xD;
               -  Participants with Grade 2 or higher residual toxicities from prior therapy&#xD;
                  (including Grade 2 or higher peripheral neuropathy or any grade neuropathy with&#xD;
                  pain; excluding alopecia). This includes recovery from any major surgery. Note:&#xD;
                  Participants with planned surgical to be conducted under local anesthesia may&#xD;
                  participate. Kyphoplasty or vertebroplasty are not considered major surgery.&#xD;
&#xD;
          8. Has uncontrolled clinically significant cardiac disease, including myocardial&#xD;
             infarction within 6 months before date of study entry or unstable or uncontrolled&#xD;
             angina, congestive heart failure, New York Heart Association (NYHA) Class III-IV,&#xD;
             uncontrolled cardiac arrhythmia (Grade 2 or higher).&#xD;
&#xD;
          9. With ongoing or active systemic infection requiring intravenous IV medical management&#xD;
             ; participants with known human immunodeficiency virus- Ribonucleic acid (HIV-RNA)&#xD;
             positivity; participants with hepatitis B virus (HBV) surface antigen or core antibody&#xD;
             positivity; and participants with known hepatitis C virus-RNA positivity. Note:&#xD;
             Participants who have positive hepatitis B core antibody can be enrolled but must have&#xD;
             hepatitis B virus- deoxyribonucleic acid (DNA) negative. Participants who have&#xD;
             positive hepatitis C antibody can be enrolled but must have hepatitis C virus-RNA&#xD;
             negativity.&#xD;
&#xD;
             Note: Participants who are already enrolled at the time of Amendment 02 should have&#xD;
             local HBV testing performed as soon as possible for HBV surface antigen, e antigen,&#xD;
             core antibody, and DNA. If any of these tests is positive, consult a physician with&#xD;
             expertise in managing HBV for guidance regarding stopping daratumumab, starting HBV&#xD;
             antiviral therapy, and remaining on study.&#xD;
&#xD;
         10. Diagnosed or treated for another malignancy within 2 years before randomization or&#xD;
             previously diagnosed with another malignancy and have any evidence of residual&#xD;
             disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type&#xD;
             are not excluded if they have undergone complete resection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218-1230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCRI - Florida Cancer Specialists - Panhandle</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Center - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCRI - Tennessee Oncology - Nashville - Centennial</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>58014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <state>Olomoucky</state>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Kralovske Vinohrady</name>
      <address>
        <city>Praha 10</city>
        <state>Praha</state>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Ostrava</name>
      <address>
        <city>Ostrava - Poruba</city>
        <state>Severomoravsky KRAJ</state>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologicka klinika Vseobecna fakultni nemocnice v Praze a 1</name>
      <address>
        <city>Praha</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-france</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez</name>
      <address>
        <city>Lille Cedex</city>
        <state>NORD Pas-de-calais</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel Dieu</name>
      <address>
        <city>Nantes Cedex 1</city>
        <state>PAYS DE LA Loire</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <state>Rhone-alpes</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evaggelismos General Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandra General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras Panagia I Voithia</name>
      <address>
        <city>Patras</city>
        <state>Peloponnese</state>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <state>Friesland</state>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-holland</state>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis Dordwijk</name>
      <address>
        <city>Dordrecht</city>
        <state>South Holland</state>
        <zip>3300 AK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-holland</state>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>93-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. Ks. B. Markiewicza</name>
      <address>
        <city>Brzozow</city>
        <state>Podkarpackie</state>
        <zip>36-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpitale Pomorskie Spolka z ograniczona odpowiedzialnoscia</name>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich</name>
      <address>
        <city>Chorzow</city>
        <state>Slaskie</state>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Greece</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <keyword>Ixazomib</keyword>
  <keyword>Daratumumab</keyword>
  <keyword>Dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

